drugset / Trial / NCT03516526
Towards Personalized Dosing of Natalizumab in Multiple Sclerosis
Phase 4
Completed
61 enrolled
Amsterdam UMC, location VUmc
Erasmus Medical Center · collabOLVG · collabProthya Biosolutions · collabRijnstate Hospital · collabSt. Antonius Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
A prospective clinical trial with the aim of maintaining drug efficacy of natalizumab while extending dose intervals guided by drug concentrations in patients with relapsing remitting multiple sclerosis.
Timeline
- Start
- 2016-11-03
- Primary completion
- 2019-06-21
- Completion
- 2019-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | natalizumab | Monoclonal antibody | — | — |